Plasmodium vivax Controlled Human Malaria Infection - Progress and Prospects

详细信息    查看全文

• 作者：Ruth O. Payne¹ ; ² ; ^{ruth.payne@ndm.ox.ac.uk} ; Paul M. Griffin³ ; ⁴ ; ⁵ ; ⁶ ; James S. McCarthy³ ; ⁶ ; Simon J. Draper¹ ; ^{simon.draper@ndm.ox.ac.uk}
• 关键词：vivax ; CHMI ; malaria ; IBSM
• 刊名：Trends in Parasitology
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：33
• 期：2
• 页码：141-150
• 全文大小：1325 K
• 卷排序：33

文摘

Modern controlled human malaria infection (CHMI) clinical trials have almost entirely focussed on Plasmodium falciparum, providing a highly informative means to investigate host–pathogen interactions as well as assess potential new prophylactic and therapeutic interventions. However, in recent years, there has been renewed interest in Plasmodium vivax, with CHMI models developed by groups in Colombia, the USA, and Australia. This review summarizes the published experiences, and examines the advantages and disadvantages of the different models that initiate infection either by mosquito bite or using a blood-stage inoculum. As for P. falciparum, CHMI studies with P. vivax will provide a platform for early proof-of-concept testing of drugs and vaccines, accelerating the development of novel interventions.